Investigational drug · Phase 3
TBI-1301
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Synovial Sarcomas.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "TBI-1301"
First trial start
2026
Jan 5, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TBI-1301", any sponsor or status.
Conditions studied
As listed on its trial records.
- Synovial Sarcomas
Largest trials
Live from ClinicalTrials.gov: studies naming "TBI-1301" as an intervention, largest first.
- Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid TumorsActive, not recruiting
University Health Network, TorontoAcademic, hospital or other
NCT02869217 · 22 participants (planned) · Start Sep 2016 · Primary completion Nov 2026
Drug: Cyclophosphamide; TBI-1301 and 1 more · For: NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients; Synovial Sarcoma; Melanoma and 5 more
Sites: Toronto, Canada
University of Southern CaliforniaAcademic, hospital or other
NCT05989828 · 20 participants (planned) · Start Dec 17, 2024 · Primary completion Dec 31, 2027
Drug: Aldesleukin; Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes and 2 more · For: Triple Negative Breast Cancer
Sites: Los Angeles, California
- Investigator Initiated Phase 1 Study of TBI-1301Status unknown
Mie UniversityAcademic, hospital or other
NCT02366546 · 9 participants · Start Mar 2015 · Primary completion Sep 2018
Drug: TBI-1301; Cyclophosphamide and 1 more · For: Solid Tumors
Sites: Tsu, Japan
Takara Bio Inc.Industry
NCT03250325 · 8 participants · Start Sep 20, 2017 · Primary completion Jan 23, 2020
Drug: TBI-1301; Cyclophosphamide · For: Synovial Sarcoma
Sites: Sapporo, Japan; Tsu, Japan; Osaka, Japan · 5 sites in all
- Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial SarcomaPivotal-lookingRecruiting
Takara Bio Inc.Industry
NCT07174427 · 5 participants (planned) · Start Jan 5, 2026 · Primary completion Mar 2032
Drug: TBI-1301; Cyclophosphamide and 1 more · For: Synovial Sarcomas
Sites: Osaka, Japan; Fukuoka, Japan; Kashiwa, Japan
Newest research
PubMed records naming it or its code names, newest first.
- Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial.
Kawai A, Ishihara M, Nakamura T, et al. · Clin Cancer Res 2023
- NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
Ishihara M, Kitano S, Kageyama S, et al. · J Immunother Cancer 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.